BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Gilead Sciences Ireland signs MoU to strengthen public health collaboration in Abu Dhabi

May 16, 2025 | News

To focus on blood-borne viruses, including hepatitis B (HBV), hepatitis C (HCV), and HIV



The Abu Dhabi Public Health Centre (ADPHC) has signed a two-year Memorandum of Understanding (MoU) with Gilead Sciences Ireland to enhance disease prevention, early detection, and public awareness in key health areas in Abu Dhabi Emirate.

The MoU establishes a framework for collaboration between ADPHC and Gilead Sciences across two core pillars: disease awareness and education campaigns and screening and early detection and diagnosis. The partnership will focus on blood-borne viruses, including hepatitis B (HBV), hepatitis C (HCV), and HIV.

Key activities under the MoU include co-developing public awareness campaigns across digital and traditional platforms, promoting proactive screening among high-risk populations, and joint initiatives to align local practices with global standards of care. Additionally, both parties will explore digital solutions to enhance patient tracking and improve referral and follow-up mechanisms.

ADPHC, the government entity leading Abu Dhabi's public health agenda, aims to boost the population's overall health through integrated prevention, screening, and intervention systems. In 2024, the Centre released its Public Health System Strengthening Report (PHSSR), emphasising the need to target non-communicable diseases and improve early detection through proactive campaigns and systemic enhancements.

Through the MoU, Gilead Sciences will leverage its international expertise and local presence to support Abu Dhabi's goals of enhancing healthcare awareness, optimising screening protocols, and improving care linkages across the health system.